2/6
12:22 am
arwr
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
2/5
08:28 pm
arwr
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]
2/5
04:05 pm
arwr
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Low
Report
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
2/3
08:41 pm
arwr
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]
Medium
Report
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]
2/3
09:29 am
arwr
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million [Yahoo! Finance]
Medium
Report
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million [Yahoo! Finance]
1/27
07:42 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]
1/27
07:30 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
1/23
05:06 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/22
09:04 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at B. Riley from $61.00 to $101.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at B. Riley from $61.00 to $101.00. They now have a "buy" rating on the stock.
1/21
10:17 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $85.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $85.00 to $100.00. They now have a "buy" rating on the stock.
1/20
04:30 pm
arwr
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Medium
Report
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
1/19
05:21 pm
arwr
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory [Yahoo! Finance]
1/13
10:48 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.
1/10
08:41 pm
arwr
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? [Yahoo! Finance]
Low
Report
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? [Yahoo! Finance]
1/9
12:27 pm
arwr
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data [Yahoo! Finance]
Low
Report
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data [Yahoo! Finance]
1/8
06:17 am
arwr
Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants [Yahoo! Finance]
1/7
11:05 pm
arwr
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Low
Report
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
1/7
07:12 pm
arwr
ARWR: Encouraging Early Data for Obesity Programs… [Yahoo! Finance]
Low
Report
ARWR: Encouraging Early Data for Obesity Programs… [Yahoo! Finance]
1/7
01:18 pm
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $50.00 to $85.00. They now have a "neutral" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $50.00 to $85.00. They now have a "neutral" rating on the stock.
1/7
10:35 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Morgan Stanley from $48.00 to $81.00. They now have an "equal weight" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Morgan Stanley from $48.00 to $81.00. They now have an "equal weight" rating on the stock.
1/7
08:33 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Chardan Capital from $60.00 to $80.00. They now have a "buy" rating on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Chardan Capital from $60.00 to $80.00. They now have a "buy" rating on the stock.
1/7
07:41 am
arwr
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China [Yahoo! Finance]
1/7
07:30 am
arwr
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Medium
Report
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
1/6
06:14 pm
arwr
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Medium
Report
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
1/6
03:10 pm
arwr
Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update [Seeking Alpha]
Low
Report
Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update [Seeking Alpha]